Literature DB >> 33911007

Nanoparticles Displaying Allergen and Siglec-8 Ligands Suppress IgE-FcεRI-Mediated Anaphylaxis and Desensitize Mast Cells to Subsequent Antigen Challenge.

Shiteng Duan1, Britni M Arlian1, Corwin M Nycholat1, Yadong Wei2, Hiroaki Tateno1, Scott A Smith3, Matthew S Macauley1, Zhou Zhu4, Bruce S Bochner5, James C Paulson6.   

Abstract

Siglec-8 is an inhibitory receptor expressed on eosinophils and mast cells. In this study, we took advantage of a novel Siglec-8 transgenic mouse model to assess the impact of modulating IgE-dependent mast cell degranulation and anaphylaxis using a liposomal platform to display an allergen with or without a synthetic glycan ligand for Siglec-8 (Sig8L). The hypothesis is that recruitment of Siglec-8 to the IgE-FcεRI receptor complex will inhibit allergen-induced mast cell degranulation. Codisplay of both allergen and Sig8L on liposomes profoundly suppresses IgE-mediated degranulation of mouse bone marrow-derived mast cells or rat basophilic leukemia cells expressing Siglec-8. In contrast, liposomes displaying only Sig8L have no significant suppression of antigenic liposome-induced degranulation, demonstrating that the inhibitory activity by Siglec-8 occurs only when Ag and Sig8L are on the same particle. In mouse models of anaphylaxis, display of Sig8L on antigenic liposomes completely suppresses IgE-mediated anaphylaxis in transgenic mice with mast cells expressing Siglec-8 but has no protection in mice that do not express Siglec-8. Furthermore, mice protected from anaphylaxis remain desensitized to subsequent allergen challenge because of loss of Ag-specific IgE from the cell surface and accelerated clearance of IgE from the blood. Thus, although expression of human Siglec-8 on murine mast cells does not by itself modulate IgE-FcεRI-mediated cell activation, the enforced recruitment of Siglec-8 to the FcεRI receptor by Sig8L-decorated antigenic liposomes results in inhibition of degranulation and desensitization to subsequent Ag exposure.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33911007      PMCID: PMC8113104          DOI: 10.4049/jimmunol.1901212

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Siglecs as Immune Cell Checkpoints in Disease.

Authors:  Shiteng Duan; James C Paulson
Journal:  Annu Rev Immunol       Date:  2020-01-27       Impact factor: 28.527

2.  Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.

Authors:  Jeremy A O'Sullivan; Daniela J Carroll; Yun Cao; Adriano N Salicru; Bruce S Bochner
Journal:  J Allergy Clin Immunol       Date:  2017-07-20       Impact factor: 10.793

Review 3.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

4.  A chimeric human-cat fusion protein blocks cat-induced allergy.

Authors:  Daocheng Zhu; Christopher L Kepley; Ke Zhang; Tetsuya Terada; Takechiyo Yamada; Andrew Saxon
Journal:  Nat Med       Date:  2005-03-27       Impact factor: 53.440

5.  Allergen-specific IgG antibody signaling through FcγRIIb promotes food tolerance.

Authors:  Oliver T Burton; Jaciel M Tamayo; Amanda J Stranks; Kyle J Koleoglou; Hans C Oettgen
Journal:  J Allergy Clin Immunol       Date:  2017-05-04       Impact factor: 10.793

Review 6.  Treatment strategies for allergy and asthma.

Authors:  Stephen T Holgate; Riccardo Polosa
Journal:  Nat Rev Immunol       Date:  2008-02-15       Impact factor: 53.106

7.  Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice.

Authors:  Laurent L Reber; Thomas Marichal; Kaori Mukai; Yoshihiro Kita; Suzumi M Tokuoka; Axel Roers; Karin Hartmann; Hajime Karasuyama; Kari C Nadeau; Mindy Tsai; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2013-08-01       Impact factor: 10.793

8.  Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice.

Authors:  Yu Liu; Yongtao Sun; Lee-Jah Chang; Newton Li; Huabin Li; Yanni Yu; Paul J Bryce; Leslie C Grammer; Robert P Schleimer; Daocheng Zhu
Journal:  J Allergy Clin Immunol       Date:  2012-11-27       Impact factor: 10.793

9.  A single glycan on IgE is indispensable for initiation of anaphylaxis.

Authors:  Kai-Ting C Shade; Barbara Platzer; Nathaniel Washburn; Vinidhra Mani; Yannic C Bartsch; Michelle Conroy; Jose D Pagan; Carlos Bosques; Thorsten R Mempel; Edda Fiebiger; Robert M Anthony
Journal:  J Exp Med       Date:  2015-03-30       Impact factor: 14.307

10.  Omalizumab facilitates rapid oral desensitization for peanut allergy.

Authors:  Andrew J MacGinnitie; Rima Rachid; Hana Gragg; Sara V Little; Paul Lakin; Antonella Cianferoni; Jennifer Heimall; Melanie Makhija; Rachel Robison; R Sharon Chinthrajah; John Lee; Jennifer Lebovidge; Tina Dominguez; Courtney Rooney; Megan Ott Lewis; Jennifer Koss; Elizabeth Burke-Roberts; Kimberly Chin; Tanya Logvinenko; Jacqueline A Pongracic; Dale T Umetsu; Jonathan Spergel; Kari C Nadeau; Lynda C Schneider
Journal:  J Allergy Clin Immunol       Date:  2016-09-05       Impact factor: 10.793

View more
  9 in total

1.  Suppressing Immune Responses Using Siglec Ligand-Decorated Anti-receptor Antibodies.

Authors:  Maidul Islam; Britni M Arlian; Fabian Pfrengle; Shiteng Duan; Scott A Smith; James C Paulson
Journal:  J Am Chem Soc       Date:  2022-05-20       Impact factor: 16.383

Review 2.  Temporal Modulation of Drug Desensitization Procedures.

Authors:  Razvan Costin Stan
Journal:  Curr Issues Mol Biol       Date:  2022-02-08       Impact factor: 2.976

3.  Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease.

Authors:  Anabel Gonzalez-Gil; Ryan N Porell; Steve M Fernandes; Eila Maenpaa; T August Li; Tong Li; Philip C Wong; Kazuhiro Aoki; Michael Tiemeyer; Zaikuan J Yu; Benjamin C Orsburn; Namandjé N Bumpus; Russell T Matthews; Ronald L Schnaar
Journal:  J Biol Chem       Date:  2022-04-20       Impact factor: 5.486

Review 4.  Siglec Signaling in the Tumor Microenvironment.

Authors:  Eline J H van Houtum; Christian Büll; Lenneke A M Cornelissen; Gosse J Adema
Journal:  Front Immunol       Date:  2021-12-13       Impact factor: 7.561

5.  The Inhibitory Receptor Siglec-8 Interacts With FcεRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation.

Authors:  Wouter Korver; Alan Wong; Simon Gebremeskel; Gian Luca Negri; Julia Schanin; Katherine Chang; John Leung; Zachary Benet; Thuy Luu; Emily C Brock; Kenneth Luehrsen; Alan Xu; Bradford A Youngblood
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

Review 6.  Mouse Models of Food Allergy in the Pursuit of Novel Treatment Modalities.

Authors:  Johanna M Smeekens; Michael D Kulis
Journal:  Front Allergy       Date:  2021-12-15

7.  Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells.

Authors:  Piper A Robida; Clayton H Rische; Netali Ben-Baruch Morgenstern; Rethavathi Janarthanam; Yun Cao; Rebecca A Krier-Burris; Wouter Korver; Alan Xu; Thuy Luu; Julia Schanin; John Leung; Marc E Rothenberg; Joshua B Wechsler; Bradford A Youngblood; Bruce S Bochner; Jeremy A O'Sullivan
Journal:  Cells       Date:  2022-03-28       Impact factor: 7.666

8.  Novel peanut-specific human IgE monoclonal antibodies enable screens for inhibitors of the effector phase in food allergy.

Authors:  Jada Suber; Yugen Zhang; Ping Ye; Rishu Guo; A Wesley Burks; Michael D Kulis; Scott A Smith; Onyinye I Iweala
Journal:  Front Immunol       Date:  2022-09-29       Impact factor: 8.786

Review 9.  Siglec Ligands.

Authors:  Anabel Gonzalez-Gil; Ronald L Schnaar
Journal:  Cells       Date:  2021-05-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.